Western Oncolytics Signs Agreement with Pfizer to Move its Gene Therapy Through Phase I Trials

Western Oncolytics and Pfizer have signed an agreement to advance Western Oncolytics’ novel preclinical oncolytic vaccinia virus, WO-12, through Phase I clinical trials. Under the agreement, Pfizer has the exclusive option to acquire the drug.